Literature DB >> 19092781

Accruing preclinical evidence about metabotropic glutamate 5 receptor antagonists as treatments for drug dependence highlights the irreplaceable contributions of animal studies to the discovery of new medications for human disorders.

Athina Markou1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19092781      PMCID： PMC2654201          DOI： 10.1038/npp.2008.218

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN： 0893-133X            Impact factor:   7.853


× No keyword cloud information.
  7 in total

1.  Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice.

Authors:  C Chiamulera; M P Epping-Jordan; A Zocchi; C Marcon; C Cottiny; S Tacconi; M Corsi; F Orzi; F Conquet
Journal:  Nat Neurosci       Date:  2001-09       Impact factor: 24.884

Review 2.  The neural basis of addiction: a pathology of motivation and choice.

Authors:  Peter W Kalivas; Nora D Volkow
Journal:  Am J Psychiatry       Date:  2005-08       Impact factor: 18.112

Review 3.  Rethinking the paradigms that inform behavioral treatment research for substance use disorders.

Authors:  Jon Morgenstern; James R McKay
Journal:  Addiction       Date:  2007-07-04       Impact factor: 6.526

4.  mGluR5 antagonism attenuates methamphetamine reinforcement and prevents reinstatement of methamphetamine-seeking behavior in rats.

Authors:  Justin T Gass; Megan P H Osborne; Noreen L Watson; Jordan L Brown; M Foster Olive
Journal:  Neuropsychopharmacology       Date:  2008-09-17       Impact factor: 7.853

5.  Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist.

Authors:  E Tatarczyńska; A Klodzińska; E Chojnacka-Wójcik; A Palucha; F Gasparini; R Kuhn; A Pilc
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

Review 6.  Role of the glutamatergic system in nicotine dependence : implications for the discovery and development of new pharmacological smoking cessation therapies.

Authors:  Matthias E Liechti; Athina Markou
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 7.  Removing obstacles in neuroscience drug discovery: the future path for animal models.

Authors:  Athina Markou; Christian Chiamulera; Mark A Geyer; Mark Tricklebank; Thomas Steckler
Journal:  Neuropsychopharmacology       Date:  2008-10-01       Impact factor: 7.853
  7 in total
  4 in total

1.  In vivo positron emission tomography imaging with [¹¹C]ABP688: binding variability and specificity for the metabotropic glutamate receptor subtype 5 in baboons.

Authors:  Christine DeLorenzo; Matthew S Milak; Kathleen G Brennan; J S Dileep Kumar; J John Mann; Ramin V Parsey
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-01-29       Impact factor: 9.236

Review 2.  Assessing behavioural and cognitive domains of autism spectrum disorders in rodents: current status and future perspectives.

Authors:  Martien J Kas; Jeffrey C Glennon; Jan Buitelaar; Elodie Ey; Barbara Biemans; Jacqueline Crawley; Robert H Ring; Clara Lajonchere; Frederic Esclassan; John Talpos; Lucas P J J Noldus; J Peter H Burbach; Thomas Steckler
Journal:  Psychopharmacology (Berl)       Date:  2013-09-19       Impact factor: 4.530

3.  In vivo variation in metabotropic glutamate receptor subtype 5 binding using positron emission tomography and [11C]ABP688.

Authors:  Christine DeLorenzo; J S Dileep Kumar; J John Mann; Ramin V Parsey
Journal:  J Cereb Blood Flow Metab       Date:  2011-07-27       Impact factor: 6.200

4.  Benzimidazoles as Potent and Orally Active mGlu5 Receptor Antagonists with an Improved PK Profile.

Authors:  David Carcache; Ivo Vranesic; Joachim Blanz; Sandrine Desrayaud; Markus Fendt; Ralf Glatthar
Journal:  ACS Med Chem Lett       Date:  2010-11-02       Impact factor: 4.345
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.